Overview
Sponsored by the American College of Chest Physicians.
Program Description
The face of anticoagulation is changing. This symposium educates physicians and health-care practitioners on the latest science related to new anticoagulants. While clinicians have relied on heparin and warfarin for decades, and, more recently, on low-molecular-weight heparins and pentasaccharide preparations, newer agents are in phase III trials. The parenteral factor Xa inhibitor, idraparinux, as well as oral direct thrombin inhibitors and factor Xa inhibitors, have been investigated in thousands of patients, and they are being, or will be, considered by the US Food and Drug Administration and the European Medicines Agency within the next few years. Based on the available clinical trial data thus far, important considerations will include the relative efficacy, safety, and cost of these agents, as well as the potential for reversibility. These considerations will need to be translated into a way to select a specific agent for different prophylactic and therapeutic indications. Clinicians will need to know the advantages and disadvantages of these agents and how to use them in clinical practice. Will the heparins and coumarins be entirely replaced by new therapies?
In this web-based format, participants have the opportunity to obtain the information as it was originally presented by watching the video slide presentations on line, downloading the slides for review, or downloading a written executive summary of the presentations to read. Following their review of the presentations, participants will be asked relevant test questions as part of the evaluation process to obtain CME credit.
Educational Objectives
- Gain an enhanced ability to select the appropriate anticoagulant agent for specific populations.
- Increase your understanding of the potential ways in which physicians can reverse the effects of new anticoagulant agents in patients with active bleeding.
- Improve your understanding of the costs of care for patients with venous thromboembolism and the effectiveness of various anticoagulant agents.
Target Audience
Advanced practice nurses, cardiologists, critical care physicians, fellows-in-training, general medicine physicians, physician assistants, pulmonary physicians, registered nurses
Needs Assessment
Venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the most common preventable cause of hospital death. The approximate annual incidence of VTE in the United States is 900,000 cases, of which approximately 400,000 cases are from DVT and 500,000 are from PE. It has been estimated that about 300,000 Americans will die of PE each year. Many of these cases are preventable with current treatment; however, new treatments are on the horizon. Many new agents are in development, and physicians need to understand the similarities and differences among the new agents, specifically related to delivery method, efficacy, compliance, reversibility, and safety.
Faculty
Victor F. Tapson, MD, FCCP
Professor of Medicine
Division of Pulmonary and Critical Care
Director, Center for Pulmonary Vascular Disease
Duke University Medical Center
Durham, NC
Andrew F. Shorr, MD, MPH, FCCP
Associate Director, Pulmonary and Critical Care
Washington Hospital Center
Associate Professor of Medicine
Georgetown University
Washington, DC
Alexander G. G. Turpie, MD
Professor, Department of Medicine
McMaster University
Hamilton, ON, Canada
CME & Disclaimers
Release: March 2009
CME Expiration: December 31, 2009
Estimated completion time: 2 hours
This CME product is a Web-based activity. Participants will watch and listen to a Webcast slide presentation, and complete an activity evaluation to obtain CME.
Accreditation - Designation
The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American College of Chest Physicians designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Anyone who attended the Evidence-Based Treatment of Pulmonary Arterial Hypertension in an Evolving Environment session at CHEST 2008 when this content was presented and already claimed CME for this presentation cannot claim CME from this enduring product.
Disclosure Statement
The ACCP remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the ACCP to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the ACCP to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair, the Education Committee, or the Conflict of Interest Review Committee to ensure that such situations are properly evaluated and, if necessary, resolved. The ACCP educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all ACCP CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available on-site during all educational activities.
The following faculty members of this educational activity have disclosed to the ACCP that a relationship does exist with the respective company/organization as it relates to their presentation of material and should be communicated to the participants of this educational activity:
Victor F. Tapson, MD, FCCP
University grant monies: sanofi-Aventis
Grant monies (from industry-related sources): sanofi-aventis (clinical research), Bayer
Consultant fee, speaker bureau, advisory committee, etc: sanofi-aventis (advisory committee, consultant), Bayer, Bacchus, Biolex, Genentech
Product/procedure/technique that is considered research and is NOT yet approved for any purpose: I may be discussing new therapies for which there are clinical data but which are not yet FDA-approved. These might include thrombin inhibitors and anti-Xa inhibitors that are currently being researched.
Alexander G. G. Turpie, MD
Consultant fee, speaker bureau, advisory committee, etc: Consultant Fee, Bayer, J& J, sanofi -aventis, Pfizer, GSK, BI, Portola, Astellas
Product/procedure/technique that is considered research and is NOT yet approved for any purpose: New anticoagulants: rivaroxaban, dabigatran, apixaban, YM150, betrixaban
Andrew F. Shorr, MD, FCCP
Grant monies (from industry related sources): GSK, sanofi-aventis,
Consultant fee, speaker bureau, advisory committee, etc: GSK, sanofi-aventis
Product/procedure/technique that is considered research and is NOT yet approved for any purpose: Newer anticoagulants in clinical development, including long-acting injectibles (eg, idraparinux) and newer oral anti-Xa inhibitors, such as rivaroxaban
Disclaimer
The American College of Chest Physicians (“ACCP”) and its officers, regents, executive committee members, members, related entities, employees, representatives and other agents (collectively, “ACCP Parties”) are not responsible in any capacity for, do not warrant and expressly disclaim all liability for, any content whatsoever in any ACCP publication or other product (in any medium) and the use or reliance on any such content, all such responsibility being solely that of the authors or the advertisers, as the case may be. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any ACCP publication or other product. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the ACCP Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
CME Instructions
CME for this activity is available through December 31, 2009. To receive CME credit and print your certificate, complete an online evaluation:
- Go to www.chestnet.org, and click on the “CME Certificates” icon.
- Log in using your ACCP ID number or e-mail address on file with the ACCP. Enter your ACCP ID number, and click submit, OR, if you do not have an ACCP ID number, click on the link “Create an account here.”
- To locate the product for which you want to claim CME credit, look under the “Available CME” tab on the left navigation bar.
- Click the “Claim Credit” link next to the product to begin the certificate process.
- Complete any required posttest and evaluation. Please be sure to check the box that states you are finished with the evaluation.
- Once you submit the evaluation, your CME certificate will be created and will show under the tab, “My CME History.” You can print it at any time by clicking the “Certificate” link.
If you need help, please contact the CME Administrator via e-mail at CME@chestnet.org, or leave a voice mail message at (847) 498-8376. For faster assistance, please outline the specific problem you are having, and provide your ACCP ID and contact information.
Related Materials
Download a Written Summary (pdf)
Download the Presentation Slides (pdf)
Anticoagulation in the Next Decade: Which Agent in Which Population?
Victor F. Tapson, MD, FCCP
New Anticoagulants: Complications, Bleeding, and Reversal
Alexander G. G. Turpie, MD
Cost-Effectiveness Models in the Treatment of Venous Thromboembolism: Becoming Good Stewards
Andrew F. Shorr, MD, MPH, FCCP
Search Archives
Search the ACCP archives for CME and non-CME related material. To see our entire archive put a * in the field below and hit search.
Submit Feedback
The ACCP is interested in your feedback concerning A Physician's Perspective®.
